<DOC>
	<DOCNO>NCT00745238</DOCNO>
	<brief_summary>Background : Myotonic dystrophy lead highly heterogeneous , multisystemic symptom include myotonia , progressive muscle weakness , cardiac conduction defect , cataract , metabolic dysfunction , excessive daytime somnolence . This last symptom relate respiratory failure and/or involvement central nervous system . However metabolic disturbance could contribute . From respiratory point view disease characterise progressive appearance respiratory failure muscular origin mainly associate defect central respiratory drive . The treatment hypoventilation non-invasive ventilation ( NIV ) . It currently absolutely clear best choice criterion judge long term effectiveness NIV . The usual criterion normalisation daytime blood gas , diminution respiratory work , improvement daytime symptom improvement sleep structure . Other criterion currently little study , instance contribution interaction alveolar hypoventilation oxygen desaturation night biological deficiency systemic inflammation , glucose intolerance insulin resistance . Likewise little information interaction alveolar hypoventilation endothelial dysfunction arterial stiffness accurate predictive factor cardiovascular risk . Aim : evaluate impact NIV endothelial dysfunction patient myotonic dystrophy . The secondary objective assess impact NIV systemic inflammation , arterial stiffness , insulin-resistance , quality sleep , daytime vigilance patient . Methods : Patients chronic alveolar hypoventilation already treat long term NIV include . They initial check-up ( Visit 1 ) , interrupt NIV treatment four week ( Visit 2 ) , return NIV treatment . The last check-up do four week NIV resumption ( Visit3 ) . Expected result : It expect NIV withdrawal result deterioration cardio-vascular parameter ( endothelial function arterial stiffness ) , metabolic parameter ( insulin-resistance systemic inflammation ) , quality sleep daytime vigilance . Return NIV treatment may show improvement parameter basal state recovery .</brief_summary>
	<brief_title>Cardiovascular Consequences NIV Withdrawal Patients With Myotonic Dystrophy</brief_title>
	<detailed_description>NIV technique assist ventilation use endotracheal route interface patient ventilator . NIV positive pressure assistance involve ventilate patient mean mask adjust nose cover nose mouth . This technique recommend therapeutic strategy treatment chronic alveolar hypoventilation . It improve survival quality life , improve daytime blood gas patient suffer form chronic restrictive respiratory failure . For check-up ( 3 visit ) , patient polysomnography , complete respiratory function measurement ( Flows lung volume , CO2 sensitivity test , SNIF test , blood gaze analysis ) , test endothelial function ( peripheral arterial tone ) , test arterial stiffness ( pulse wave velocity ) , assessment systemic inflammation ( ultra sensitive CRP , TNFa , IL6 ) , assessment diurnal vigilance test ( OSLER test sleepiness scale ) assessment metabolic endocrinal function ( insulinemia , glucose blood level , Leptin , DHEA ) .</detailed_description>
	<mesh_term>Myotonic Dystrophy</mesh_term>
	<mesh_term>Myotonia</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients ( &gt; 18 yr ) suffer myotonic dystrophy already treat long term nocturnal non invasive ventilation six month chronic hypercapnic respiratory failure ( Level PaCO2 begin treatment 45 55 mmHg ) Patients use ( ) noninvasive ventilation 4 hour less 12 hour per day . Patients could associate obstructive or/and central sleep apnea . NIV treatment consider `` efficient `` : To allow improvement PaCO2 wakefulness morning use NIV compare PaCO2 begin treatment ; To allow improvement nocturnal oxymetry compare baseline ( mean nocturnal SaO2 &gt; 90 % ) . EXCLUSION CRITERIA : Patients concomitant respiratory condition contribute daytime alveolar hypoventilation . Patients judge investigator high cardiovascular risk , contraindicate NIV withdrawal . Patients cardiac failure periodic breathing . Patients acute episode respiratory failure previous month . Incapacitated patient accordance article L 11216 public health code . Patients treat oral corticosteroid oral longterm nonsteroidal antiinflammatory drug ( NSAID ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>endothelial function</keyword>
	<keyword>peripheral arterial tone</keyword>
	<keyword>systemic inflammation</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>respiratory peripheral muscular function</keyword>
</DOC>